Nature Cancer, Published online: 19 May 2026; doi:10.1038/s43018-026-01174-7

Tang et al. identify cysteinyl leukotriene receptor 1 (CysLTR1) as a critical regulator of tumor-induced myelopoiesis, suggesting CysLTR1 targeting to sensitize tumors to immune checkpoint blockade.

Cancers evade RAS-targeting molecular glues through distinct alterations that converge on disrupting synthetic complex formation, exposing strategies for improved drug design and rational combination therapy.